(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 3.58% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.86%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.09%.
Charles River Laboratories International's revenue in 2026 is $4,023,704,000.On average, 19 Wall Street analysts forecast CRL's revenue for 2026 to be $202,570,878,636, with the lowest CRL revenue forecast at $194,450,325,921, and the highest CRL revenue forecast at $214,727,099,973. On average, 17 Wall Street analysts forecast CRL's revenue for 2027 to be $212,069,464,539, with the lowest CRL revenue forecast at $199,962,458,673, and the highest CRL revenue forecast at $235,692,890,619.
In 2028, CRL is forecast to generate $218,811,984,066 in revenue, with the lowest revenue forecast at $209,411,829,105 and the highest revenue forecast at $232,789,177,830.